Islet Sciences Announces Participation at the 2012 American Transplant Congress

_{//health-fitness.news-articles.net/content/2012/ .. on-at-the-2012-american-transplant-congress.html}
^{Published in Health and Fitness on Monday, June 4th 2012 at 5:55 GMT by Market Wire}  

Islet Sciences Announces Participation at the 2012 American Transplant Congress -- NEW YORK, June 4, 2012 /PRNewswire/ --

NEW YORK, June 4, 2012 /PRNewswire/ -- Islet Sciences, Inc., (OTCBB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced that it will present at the upcoming 12th Joint Annual Meeting of the American Society of Transplant Surgeons and the American Transplantation (2012 American Transplant Congress).

The event will be held from June 2^nd - June 6^th at the John B. Hynes Convention Center in Boston, MA. Islet Sciences will present an update on work with their xenotransplantation model for islet transplantation on June 5, 2012 at 5:30 PM ET.

About Islet Sciences, Inc.

Islet Sciences is a development-stage biotechnology company with patented technologies focused on transplantation therapy for people with insulin-dependent diabetes.  The Company's transplantation technology includes methods for the culturing, isolation, maturation, and immunoprotection (microencapsulation) of islet cells. The Company's mission includes the introduction of commercial products with applications to cell-based replacement therapy in the healthcare marketplace.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements for Islet Sciences reflect current expectations, as of the date of this press release, and involve certain risks and uncertainties.   Actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors.  Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the risks described in the Islet Science's reports filed with the Securities and Exchange Commission.  The companies' further development is highly dependent on future medical and research developments and market acceptance, which is outside their control.

Investor Contact:

Jeff Ramson

ProActive Capital Resources Group

(646) 863-6893

[ jramson@proactivecrg.com ]

SOURCE Islet Sciences, Inc.